News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (339 of 393). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (16 of 393). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (38 of 393). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 291 of 393 items have one.
New microscopy technology may help detect neurological diseases before neurons die
Scientists studying amyotrophic lateral sclerosis (ALS), Parkinson's, Alzheimer's and other neurological diseases are getting unprecedented views inside brain cells, using powerful new microscopes to uncover changes that may begin long before neurons die. …
Read at Medical Xpress →Alzheimer’s may leave a mark on the brain long before plaques appear
Brain changes associated with Alzheimer’s may begin at least seven years before amyloid plaques become detectable with current PET scans. Researchers uncovered the signal by tracking healthy older adults with repeated brain imaging over nearly 20 years. …
Read at ScienceDaily → Archived copy (16 Sep 2026), Internet ArchiveFDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease
The FDA granted 510(k) clearance to Fujirebio's Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test, the first blood test cleared to help diagnose Alzheimer's in adults 55 and older with signs of cognitive decline. In FDA's review, positive results correctly identified amyloid plaques 91.7% of the time and negative results correctly ruled them out 97.3% of the time.
Why it matters: A simple blood draw can now help identify amyloid plaques without a spinal tap or PET scan, potentially speeding diagnosis and lowering costs, though FDA stressed it isn't a stand-alone diagnostic test.
Read at FDA → Archived copy (10 Oct 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.